Trial Profile
Open clinical study to assess long-term efficacy and safety of dimethyl fumarate in adults with moderate to severe chronic plaque psoriasis in real practice (DIMESKIN 1 Trial)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms DIMESKIN 1
- Sponsors Almirall S.A.
- 01 Dec 2022 Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1) assessing the efficacy and safety of DMF in patients with moderate-to-severe plaque psoriasis through 52 weeks in conditions close to real clinical practice published in the Dermatology and Therapy
- 22 Jul 2022 Status changed from recruiting to completed.
- 18 Sep 2017 New trial record